Inulin-bentonite hybrid microparticles enhance orlistat efficacy while mitigating gut microbiota disruption in a high-fat diet rat model

Orlistat is an established pharmacotherapy for metabolic syndrome (MetS); however, its clinical utility is constrained by gastrointestinal adverse effects and gut microbiota disruption. This study evaluates hybrid inulin (INU)-bentonite (BEN) microparticles (InuClay) as a microbiota-protective adjunct to orlistat therapy. In vitro lipolysis under biorelevant fasted-state conditions demonstrated that InuClay significantly reduced free fatty acid liberation relative to untreated controls and INU alone ( p < 0.01). In a 21-day high-fat diet rat model of MetS, InuClay and orlistat monotherapies reduced cumulative weight gain by 4.5% and 5.7%, respectively. Co-administration achieved a 7.7% reduction that was significantly greater than either monotherapy alone. Combination therapy also produced the greatest reduction in fasting blood glucose (27%) exceeding both InuClay monotherapy (12%) and orlistat monotherapy (16%). At the microbiota level InuClay co-administration prevented orlistat-induced Proteobacteria expansion (2.5-fold reduction versus orlistat alone) while selectively enriching butyrate-producing taxa including Lachnospiraceae (1.42-fold) and Blautia (11.8-fold) without significantly altering alpha diversity. Circulating markers of cellular injury were substantially lower with combination therapy, with lactate dehydrogenase decreased by 63% and aspartate aminotransferase by 23% versus controls. These reductions were absent with orlistat monotherapy. Collectively these findings establish InuClay as a dual-action adjunct that enhances orlistat efficacy while attenuating dysbiotic shifts and systemic markers of tissue stress. As a 21-day proof-of-concept study, this work is intended to establish the feasibility of InuClay hybrids as adjunct therapy for improving the metabolic outcomes of orlistat administration. These preliminary findings support InuClay as a promising strategy for improving translational outcomes in lipase inhibitor-based MetS management.

Authors

Institutions

Publication Details

Journal
Drug Delivery and Translational Research
Published
2026-11-17
DOI
https://doi.org/10.1007/s13346-026-02245-z
Citations
1
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
2.15
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inulin-bentonite hybrid microparticles enhance orlistat efficacy while mitigating gut microbiota disruption in a high-fat diet rat model

Clive A. Prestidge, Anthony D. Wignall, Aurelia S. Elz, Paul M. Joyce et al.
1 citations
Drug Delivery and Translational Research
Pharmacology and Obesity Treatment
2.15
article

Inulin-bentonite hybrid microparticles enhance orlistat efficacy while mitigating gut microbiota disruption in a high-fat diet rat model

Clive A. Prestidge, Anthony D. Wignall, Aurelia S. Elz, Paul M. Joyce, Hannah R. Wardill, Tahlia R. Meola, Amin Ariaee, Alex Hunter
article en
1 citations

Abstract

Orlistat is an established pharmacotherapy for metabolic syndrome (MetS); however, its clinical utility is constrained by gastrointestinal adverse effects and gut microbiota disruption. This study evaluates hybrid inulin (INU)-bentonite (BEN) microparticles (InuClay) as a microbiota-protective adjunct to orlistat therapy. In vitro lipolysis under biorelevant fasted-state conditions demonstrated that InuClay significantly reduced free fatty acid liberation relative to untreated controls and INU alone ( p < 0.01). In a 21-day high-fat diet rat model of MetS, InuClay and orlistat monotherapies reduced cumulative weight gain by 4.5% and 5.7%, respectively. Co-administration achieved a 7.7% reduction that was significantly greater than either monotherapy alone. Combination therapy also produced the greatest reduction in fasting blood glucose (27%) exceeding both InuClay monotherapy (12%) and orlistat monotherapy (16%). At the microbiota level InuClay co-administration prevented orlistat-induced Proteobacteria expansion (2.5-fold reduction versus orlistat alone) while selectively enriching butyrate-producing taxa including Lachnospiraceae (1.42-fold) and Blautia (11.8-fold) without significantly altering alpha diversity. Circulating markers of cellular injury were substantially lower with combination therapy, with lactate dehydrogenase decreased by 63% and aspartate aminotransferase by 23% versus controls. These reductions were absent with orlistat monotherapy. Collectively these findings establish InuClay as a dual-action adjunct that enhances orlistat efficacy while attenuating dysbiotic shifts and systemic markers of tissue stress. As a 21-day proof-of-concept study, this work is intended to establish the feasibility of InuClay hybrids as adjunct therapy for improving the metabolic outcomes of orlistat administration. These preliminary findings support InuClay as a promising strategy for improving translational outcomes in lipase inhibitor-based MetS management.

Drug Delivery and Translational Research
South Australian Health and Medical Research Institute (AU), Adelaide University (AU), The University of Adelaide (AU)
Good health and well-being
Openalex Percentile: Top 21%
Pharmacology and Obesity Treatment
2.15
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon